Emcure Pharmaceuticals Ltd. cuts Poviztra prices to boost obesity care access 

Key Highlights: 

• Emcure Pharma has reduced the starting price of Poviztra (Semaglutide injection) by 55%, now available at Rs. 999 per week (Rs. 3,999/month for 4 weekly doses), with revised monthly pricing across doses: 0.25 mg – Rs. 3,999; 0.5 mg – Rs. 4,999; 1 mg – Rs. 5,999; 1.7 mg – Rs. 7,999; 2.4 mg – Rs. 8,999  

• The once-weekly pen device is offered in five strengths (0.25 mg to 2.4 mg), enabling convenient dosing and improved accessibility to a globally established weight management therapy  

• As the exclusive distributor of Novo Nordisk’s semaglutide, Emcure’s price revision aims to expand patient access amid rising obesity burden in India  

Implications: 

Emcure is effectively repositioning Poviztra as a mass‑market GLP‑1 for obesity in India, using a steep 55% entry‑dose cut (now ₹3,999/month, ₹999/week) to narrow the gap with emerging semaglutide generics while keeping patients on the innovator molecule and device. 

This pricing reset should expand the eligible middle‑class pool, pressure rival GLP‑1 launches to follow suit, and help Emcure defend share as Novo Nordisk’s exclusive obesity partner by offering a full five‑strength, once‑weekly pen at a more accessible price point in a market with hundreds of millions living with general or abdominal obesity. 

Source: Emcure | Image: Emcure